Heminevrin

Heminevrin is a prescription medication that contains the active ingredient clomethiazole edisylate. It is formulated for oral administration, though exact strength and dosage form can differ between European market presentations. Classified as a thiazolyl‑derived sedative/hypnotic, Heminevrin works by modulating the GABA‑A receptor to produce calming effects. It is primarily used in the management of acute alcohol withdrawal and for short‑term sedation under medical supervision in clinical settings.

Heminevrin is indicated for specific clinical situations where rapid control of central nervous system hyperactivity is required.

- Management of acute alcohol withdrawal syndrome to reduce agitation, tremor, and risk of seizures. - Short‑term sedation for patients requiring procedural or intensive‑care sedation. - Adjunctive therapy in the treatment of severe insomnia when other agents are unsuitable. - Pre‑operative sedation to facilitate anxiolysis before surgery. - Symptom control in delirium tremens under specialist supervision.

Side effects reported with clomethiazole edisylate vary in frequency and severity.

Common: - Drowsiness or somnolence. - Dizziness or light‑headedness. - Headache. - Nausea or upset stomach. - Dry mouth.

Serious: - Respiratory depression, especially when combined with other depressants. - Marked hypotension or cardiovascular instability. - Severe allergic reactions such as anaphylaxis, skin rash, or angioedema.

Heminevrin should be prescribed with caution, considering the following safety points.

- Do not use in patients with known hypersensitivity to clomethiazole or related compounds. - Avoid in individuals with severe respiratory insufficiency or uncontrolled asthma. - Use carefully in patients with hepatic impairment; dose adjustment may be required. - Monitor for signs of dependence, tolerance, or withdrawal on prolonged therapy. - Do not discontinue abruptly; taper the dose under medical supervision. - The safety of Heminevrin during pregnancy and lactation has not been established. - Concomitant use with alcohol or other central nervous system depressants increases risk of profound sedation.

Clomethiazole edisylate can interact with several other medicines, influencing its sedative effect or safety profile.

Avoid: - Other central nervous system depressants such as benzodiazepines, opioids, barbiturates, and alcohol. - Potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin) that may increase plasma levels. - Additional GABA‑A receptor modulators that can potentiate sedation.

Use with caution: - Central nervous system stimulants (e.g., caffeine, modafinil) that may counteract sedative effects. - Antihypertensive agents, as additive hypotensive effects may occur. - Certain antidepressants (e.g., SSRIs, SNRIs) that can alter central neurotransmission. - Anticholinergic drugs, which may exacerbate dry mouth and constipation. - General anesthetic agents during surgery, requiring dose adjustments.